FDA Drug Recalls

Recalls / Class II

Class IID-0835-2022

Product

Losartan Potassium & Hydrochlorothiazide Tablets, USP, 50 mg/12.5 mg, a) 30-count bottles (NDC# 33342-050-07), b) 90-count bottles (NDC # 33342-050-10) c) 1000-count bottles (NDC # 33342-050-44), Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536

Brand name
Losartan Potassium And Hydrochlorothiazide
Generic name
Losartan Potassium And Hydrochlorothiazide
Active ingredients
Hydrochlorothiazide, Losartan Potassium
Route
Oral
NDCs
33342-050, 33342-051, 33342-052
FDA application
ANDA202289
Affected lot / code info
Lot # BLK2107B, exp. date 05/2023 BLK2101A, exp. date 01/2025 BLK2102A, exp. date 02/2025 BLK2103B, exp. date 02/2023 BLK2103C, exp. date 02/2023 BLK2104A, exp. date 05/2023

Why it was recalled

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Recalling firm

Firm
Macleods Pharma Usa Inc
Manufacturer
Macleods Pharmaceuticals Limited
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
666 Plainsboro Rd Bldg 200 Ste 230, N/A, Plainsboro, New Jersey 08536-0009

Distribution

Quantity
N/A
Distribution pattern
Product was distributed nationwide.

Timeline

Recall initiated
2022-04-15
FDA classified
2022-05-03
Posted by FDA
2022-05-11
Terminated
2023-10-13
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0835-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.